Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 2/20 | 0.34 |
| ▸ | AOC1 | P19801 | 1/20 | 0.31 |
| ▸ | PDXK | O00764 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12948943 | 0.83 | LMNA (0.65) | LMNAAOC3KDM4EALDH1A1HPGD | |
| Methane SCHEMBL15483967 | 0.82 | LMNA (0.62) | LMNAAOC3KDM4EALDH1A1HPGD | |
| SCHEMBL21279618 | 0.81 | KDM4E (0.38) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9970109 | 0.78 | LMNA (0.44) | LMNAAOC3KDM4EALDH1A1HPGD | |
| SCHEMBL9970098 | 0.76 | LMNA (0.71) | LMNAAOC3KDM4EALDH1A1HPGD | |
| SCHEMBL7880212 | 0.72 | KDM4E (0.35) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14682728 | 0.71 | LMNA (0.65) | LMNAAOC3KDM4EALDH1A1HPGD | |
| SCHEMBL9970114 | 0.68 | DPP4 (0.43) | LMNAAOC3MEN1KMT2A | |
| SCHEMBL14446395 | 0.68 | LMNA (0.39) | LMNAAOC3KDM4EALDH1A1LOX | |
| SCHEMBL25609360 | 0.68 | LMNA (0.61) | LMNAAOC3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330049-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | MTI BIOTECH, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180153827-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | MTI BIOTECH, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20140256774-A1 | METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | VANDERBILT UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-8822542-B2 | Isoketal scavengers and mitigation of disorders involving oxidative injury | VANDERBILT UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120157501-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | VANDERBILT UNIVERSITY | 2012-06-21 | — | — | US | disclosed |
| US-7705054-B1 | Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases | VANDERBILT UNIVERSITY (US) | 2010-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256774-A1 | METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | AKR1B1, NFKBIA, PTGS2 | LMNA 1062/4885AOC3 706/4885KDM4E 607/4885 |
| US-20120157501-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | PDXK, KYNU, FN3K | LMNA 2014/4885AOC3 501/4885KDM4E 1534/4885 |
| US-20230330049-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | GGT1, GGH, AKR7A2 | LMNA 1628/4885AOC3 615/4885KDM4E 444/4885 |
| US-20180153827-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | CPT1A, AKR7A2, FABP1 | LMNA 703/4885AOC3 480/4885KDM4E 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.